About Us

DIABIL-2 is a European project (Collaborative Research Project) started in October 2012 coordinated by the Assistance Publique-Hôpitaux de Paris (AP-HP, Prof. David Klatzmann) from France. Our consortium brings together 5 complementary partners: 1 small and medium enterprise called ILTOO, dedicated to the development of ultra low-dose IL-2 in novel indications including T1D, as well as Inserm-Transfert, a technology transfer / management company and 3 academic laboratories, from France, Germany and Switzerland. The project is supported by the European Commission under the Health Priority of the 7th Framework Programme.